Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer

Part of paid clinical trials in Washington D.C., District of Columbia.

Sponsor: Georgetown University
Study ID: NCT06015724
Phase: PHASE2
Status: Active Not Recruiting

Conditions

Pancreatic Ductal Adenocarcinoma
Refractory Non-Small Cell Lung Cancer

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Daratumumab — DRUG
anti-CD38 monoclonal antibody (mAb)
KRAS vaccine — BIOLOGICAL
Stimulon QS-21 and Targovax TG01
Nivolumab — DRUG
anti-PD-1 (programmed cell death protein 1) monoclonal antibody (mAb)

Study Details

The goal of this clinical trial is to test the safety and tolerability of anti-CD38 monoclonal antibody (mAb), daratumumab, in combination with KRAS vaccine (Targovax TG-01/Stimulon QS-21) when given with anti-PD-1 (programmed cell death protein 1) mAb (nivolumab) in patients with advanced non-small cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: * How well does daratumumab and nivolumab, when given with a vaccine, control or stop these types of cancer? * How well does participants bodies handle these study drugs? * Does this combination of study drugs help participants live longer? Participants will receive daratumumab, nivolumab with KRAS vaccine and have regular tests and procedures to follow how the participants are doing on these study drugs.